3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
4
Other hematologic neoplasm
2
Dermatologic
2
CNS
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Gastrointestinal
1
Classical hematology
1
Conditions
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Injections
54
pembrolizumab
40
Carboplatin
20
Bevacizumab
19
Cyclophosphamide
17
toripalimab
14
Nivolumab
14
Cisplatin
14
tislelizumab
13
fludarabine
13
Specimen Handling
13
Paclitaxel
13
Interviews as Topic
13
Pemetrexed
12
Standard of Care
11
Practice Guidelines as Topic
11
Oxaliplatin
11
Fluorouracil
10
Cetuximab
10
atezolizumab
9
Educational Status
9
Docetaxel
9
Capecitabine
9
Leucovorin
8
Methods
7
Etoposide
7
Early Intervention, Educational
7
spartalizumab
6
olaparib
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Influenza Vaccines
×
Other solid neoplasm
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled